Skip to content

Clinical analysis of G-type robot assisted pancreaticoduodenectomy in the treatment of ampullary tumors

Clinical analysis of G-type robot assisted pancreaticoduodenectomy in the treatment of ampullary tumors

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100053744
Enrollment
Unknown
Registered
2021-11-28
Start date
2019-07-27
Completion date
Unknown
Last updated
2022-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ampullary tumor

Interventions

Experimental group:Robot assisted therapy

Sponsors

The First Hospital of Shanxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. There is a clear pathological diagnosis of ampullary tumor, that is, the cancer tissue has infiltrated into the submucosa, entered the muscle layer or has passed through the muscle layer to reach the serosa (T1b or above, N0 or above); 2. Preoperative B-ultrasound and CT examination showed no distant organ metastasis (M0); 3. No abnormality was found in preoperative blood routine, blood type, coagulation function, liver and kidney function (full biochemical items) and infection screening, and the detection of tumor markers (CEA, CA199, CA72.4, CA242) was complete; 4. The primary tumor can be resected by R0; 5. No other important related diseases (such as other malignant tumors, serious heart and central nervous system diseases, etc.); 6. Karnofsky score >= 70; 7. Aged over 18 years old; 8. Clear awareness, able to understand and answer questions clearly; 9. Sign the informed consent form

Exclusion criteria

Exclusion criteria: 1. The general situation cannot tolerate surgery; 2. With distant metastasis; 3. Tumor diameter > 10cm; 4. Lymph node metastases fuse and surround important blood vessels and (or) tumor and surrounding tissues and organs are extensively infiltrated; 5. Ampullary tumor patients who have implemented neoadjuvant therapy or recommended neoadjuvant therapy.

Design outcomes

Primary

MeasureTime frame
radiological examination;Serum tumor markers;living conditions;

Countries

China

Contacts

Public ContactWei Zhignag

The First Hospital of Shanxi Medical University

wzgsyyy@163.com+86 13753180090

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026